How to optimize lipid-lowering therapy: Do not forget patient's non-compliance;Comment optimaliser le traitement hypolipidémiant: Ne pas oublier la problématique du défaut d'observance

Revue Medicale de Liege

Volumn 65, Issue 5-6, 2010, Pages 311-317

  Radermecker, R P ^a   Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Compliance; Dyslipidaemia; Lipid lowering therapy; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; PATIENT COMPLIANCE; REVIEW; TREATMENT RESPONSE;

ANTILIPEMIC AGENTS; DYSLIPIDEMIAS; HUMANS; MEDICATION ADHERENCE;

EID: 77954104670     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Scheen AJ, Radermecker RP, De Flines J, Ducobu J. - Actualités thérapeutiques en lipidologie. Rev Med Liège, 2007, 62, 324-328.
2. Scheen AJ. - Inertie dans la pratique médicale : causes, conséquences, solutions. Rev Med Liège, 2010, 65, 232-238.
3. Scheen AJ, Giet D. - Non-observance thérapeutique : causes, conséquences, solutions. Rev Med Liège, 2010, 65, 239-245.
4. Goldberg KC, Melnyk SD, Simel DL. - Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care, 2007, 13, 530-534.
5. Kotseva K, Wood D, De Backer G, et al. - Cardiovascular prevention guidelines in daily practice : a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet, 2009, 373, 929-940.
6. Liberopoulos EN, Florentin M, Mikhailidis DP, Elisaf MS. - Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf, 2008, 7, 717-725.
7. Ansell BJ. - Not getting to goal : the clinical costs of noncompliance. J Manag Care Pharm, 2008, 14 (6 Suppl B), 9-15.
8. Bakhai A. - The burden of coronary, cerebrovascular and peripheral arterial disease. Pharmacoeconomics, 2004, 22 (Suppl 4), 11-18. (Pubitemid 40066089)
9. De Backer G, De Bacquer D, Brohet C, et al. - Recommandations relatives à la prévention des maladies cardio-vasculaires en pratique clinique. Groupe de Travail Belge de Prévention des Maladies Cardio-vasculaires. Rev Med Liège, 2005, 60, 163-172.
10. Scheen AJ. - Choix médicamenteux influencés par les comorbidités connues et nouvellement diagnostiquées chez un patient à risques multiples. Rev Med Liège, 2009, 63, 693-697.
11. Scheen AJ. - La non observance thérapeutique : problème majeur pour la prévention des maladies cardiovasculaires. Rev Med Liège, 2000, 54, 914-920.
12. Pharmaceutical Group of the European Union Representing European Community Pharmacists. Rue du Luxembourg 19-21.| B-1000 Brussels www.pgeu.eu
13. Benner JS, Glynn RJ, Mogun H, et al. - Long-term persistence in use of statin therapy in elderly patients. JAMA, 2002, 288, 495-497. (Pubitemid 34787476)
14. Yang CC, Jick SS, Testa MA. - Discontinuation and switching of therapy after initiation of lipid-lowering drugs : the effects of comorbidities and patient characteristics. Br J Clin Pharmacol, 2003, 56, 84-91. (Pubitemid 36886492)
15. Ho PM, Spertus JA, Masoudi FA, et al. - Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med, 2006, 166, 1842-1847. (Pubitemid 44455166)
16. Benner JS, Pollack MF, Smith TW, et al. - Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm, 2005, 62, 1468-1475.
17. Bates TR, Connaughton VM, Watts GF. - Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother, 2009, 10, 973-985.
18. Scheen AJ. - Aspects pharmaco-économiques des traitements hypolipidémiants. Rev Med Liège, 1997, 52, 16-21.
19. Morisky DE, Green LW, Levine DM. - Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care, 1986, 24, 67-74.
20. Lee SS, Cheung PP, Chow SS. - Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol, 2004, 44, 632-639.
21. Marquez-Contreras E, Casado-Martinez JJ, Lopez A, et al. - Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria, 1998, 22, 79-84.
22. Jandrain BJ, Ernest Ph, Radermecker RP, Scheen AJ. - Stratégies pour éviter l'inertie et la non observance dans les essais cliniques. Rev Med Liège, 2010, 65, 246-249.
23. Scheen AJ, Kulbertus H. - Prévention cardio-vasculaire par les statines : faut-il encore doser le cholestérol ? Rev Med Liège, 2003, 58, 191-197.
24. Radermecker RP, Scheen AJ. - Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholestérolémiant. Rev Med Suisse, 2006, 2, 1910-1915.
25. Scheen AJ, Radermecker RP. - Combinaison fixe ézétimibe/ simvastatine (INEGY®). Rev Med Liège, 2007, 62, 585-590.
26. Yiu KH, Cheung BM, Tse HF. - A new paradigm for managing dyslipidemia with combination therapy : laropiprant + niacin + simvastatin. Expert Opin Investig Drugs, 2010, 19, 437-449.
27. Paolini JF, Mitchel YB, Reyes R, et al. - Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol, 2008, 101, 625-630.
28. Schwed A, Fallab CL, Burnier M, et al. - Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol, 1999, 39, 402-409. (Pubitemid 29159830)
29. Scheen AJ, Lefèbvre PJ, Kulbertus H. - Prévention cardio- vasculaire globale : la «polypill», une solution pour vaincre l'inertie clinique et le manque d'observance ? Rev Med Liège, 2010, 65, 267-272.